Pan-Tam Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-Pd-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer

Cancer Research - United States
doi 10.1158/0008-5472.can-18-2614
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy Against Triple-Negative Human Breast Cancer Cells

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-Ron ADC Zt/G4-Mmae

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

PD-L1 Expression in Triple-Negative Breast Cancer

Cancer immunology research
Cancer ResearchImmunology
2014English

PIM-1 Kinase: A Potential Biomarker of Triple-Negative Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

7. PD-L1 in Triple Negative Breast Cancer – Optimal Testing for Therapeutic Efficacy

Pathology
Forensic MedicinePathology
2020English

Therapeutic Activity of DCC-2036, a Novel Tyrosine Kinase Inhibitor, Against Triple-Negative Breast Cancer Patient-Derived Xenografts by Targeting AXL/MET

International Journal of Cancer
Cancer ResearchOncology
2018English

Vitamin D Enhances the Efficacy of Photodynamic Therapy in a Murine Model of Breast Cancer

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2015English

The Efficacy of Betulinic Acid in Triple-Negative Breast Cancer

SAGE Open Medicine
Medicine
2014English

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer

Cancers
Cancer ResearchOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy